“Change is the only constant” is an ageless truth. In the search for age-related biomarkers, it is also a prosaic confounding factor.
Age-related biomarkers will be critical for the development of antiaging therapeutics. “Nobody is planning to do a life span study in humans,” Eric Verdin told the audience at the 10th Conference on Aging Research and Drug Development in Copenhagen on Monday. “Hence the need for … surrogate markers.”
“Change is the only constant” is an ageless truth. In the search for age-related biomarkers, it is also a prosaic confounding factor. Age-related biomarkers will be critical for the development of antiaging therapeutics. “Nobody is planning to do a life span study in humans,” Eric Verdin told the audience at the 10th Conference on Aging Research and Drug Development in Copenhagen on Monday. “Hence the need for … surrogate markers.” And “we are not there … we are actually quite far from there.”
Despite continual investment in research focused on high-grade serous ovarian cancer (HGSOC), the 5-year survival rate of ∼30% for most patients has remained unchanged for decades. While ≤20% of HGSOC patients present with treatment-refractory disease, therapeutic strategies have not changed outcomes for these patients in 40 years.
To identify candidate therapeutic targets for cancers with SF3B1 hotspot mutations, drug-sensitivity screening of an in-house library of 80 small-molecule inhibitors resulted in the identification of a series of candidate SF3B1 mutant (SF3B1[MUT]) synthetic lethal drugs that led to significant reduction of survival in SF3B1(K700E) cells.
Researchers in London have cut through the complexity of the genetics underlying bipolar spectrum disorder (BSD) to discover single nucleotide polymorphisms they say are specific enough to form the basis of the first ever biomarker-based diagnostic test in psychiatry.
Characterized by periods of deep and profound depression alternating with periods of excessive mania mood swings with diminished sleep, bipolar spectrum disorder (BSD) affected an estimated 40 million people globally in 2019 in the U.S. with a major part of the problem attributed to delays in diagnosis including a mean time of 5-13 years. These delays in BSD diagnosis exert lifelong impacts including heightened suicide risk, relationship strains, impaired work/education performance, significant financial burdens and increased risk for cardiovascular disease.
Researchers from Harvard Medical School, Yale University and University of Leiden have uncovered two new potential biomarkers of dysregulated glucose metabolism in Alzheimer’s disease (AD). Glucose hypometabolism is consistently observed in AD but the molecular changes behind this are unclear. Findings from recent research have indicated dysregulation of glycolysis markers in AD cerebrospinal fluid (CSF) and tissue.
Researchers from Washington University in St. Louis reported data validating microtubule-binding region (MTBR) of tau containing the residue 243 (MTBR-tau243) as a new cerebrospinal fluid (CSF) biomarker specific for insoluble tau aggregates in Alzheimer’s disease (AD).
Researchers from Murdoch Children’s Research Institute presented data from a study that linked recessive variants in the SART3 gene with a novel neurodevelopmental syndrome.
Researchers from Children’s Hospital of Philadelphia presented data from a study that linked variants in DNA methyltransferase 1-associated protein 1 (DMAP1) to a novel neurodevelopmental disorder.
RSS
